1. 信涛-2017WCLC免疫治疗进展.11.18.pptxVIP

IImmunotherapy in Non-Small Cell Lung Cancer 2O17 WCLC ;2017WCLC免疫治疗进展;4;肺癌治疗：从细胞毒药物化疗时代跨入免疫治疗时代;免疫治疗与标准二线化疗比较;Primary endpoint (first 850 enrolled patients): OS in the ITT population (ITT850) Data cutoff: 23 January, 2017; Minimum follow-up: 26 months;Landmark 2-year overall survival in OAK;Long-term survival benefit by histology and PD-L1 expression subgroups; Atezolizumab (anti–PD-L1) has demonstrated OS benefit over docetaxel (HR, 0.73 [95% CI: 0.53, 0.99]) in a randomized Phase II study, POPLAR, in patients with advanced NSCLC1This benefit has been confirmed in the randomized Phase III study OAK2 This presentation describes survival results from POPLAR after a minimum of 3 years follow-up Data cutoff: 7 April 2017; Median follow-up: 38 months;Improved OS with atezolizumab vs docetaxel was observed at 1, 2 and 3 years ORR with both atezolizumab and docetaxel was 15% Median duration of response: Atezolizumab: 22.3 mo (range 2.9 to 38.7+) Docetaxel: 7.2 mo (range, 1.5+ to 15.4) Treatment-related Grade 3-4 AEs: Atezolizumab: 14% Docetaxel: 40%;3-year overall survival with atezolizumab vs docetaxel by histology and PD-L1 expression subgroups;免疫治疗二线联合或局部治疗后维持治疗NSCLC;14;Progression-free Survival in subgroups;非鳞癌 vs 鳞癌a;PACIFIC: Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study;PACIFIC Primary Endpoint: PFS by BICR ;Oligometastatic disease is seen in 7% of all NSCLC Emerging data indicate that LAT may improve outcomes It is unclear if further treatment beyond LAT is beneficial Immunotherapy may be more effective in a minimal residual disease state;Trial Schema;Median Age;6 month OS;PD-1/PD-L1抑制剂二线治疗疗效好且安全性明显优于化疗;Nivolumab, atezolizumab: 所有患者（无论PD-L1表达） Pembrolizumab：PD-L1? 1%的患者;化疗联合免疫治疗一线治疗NSCLC;First-Line Therapy for Advanced Nonsquamous NSCLC: KEYNOTE-021 Cohort G Update Cohort G;Overall Survival; First-Line Nivolumab + Chemotherapy in NSCLC CheckMate 012 3-Year Update;CheckMate 012: First-Line Nivolumab + Chemotherap